Methodology Core This Core focuses on economic evaluation approaches, tools, and measures to support new and existing interdisciplinary research collaborations. Despite decades of research supporting a chronic disease approach to substance use disorder treatment and recovery, uptake and sustainment remain low. Some of the most important factors inhibiting adoption of evidence-based practices are concerns about the potential burden on staff and other resources, as well as overall budget impact. Changing current practices requires not only clinical evidence, but also consideration of additional costs and the reallocation of existing resources that will result from the changes. Economic analysis can directly address these issues by providing a detailed accounting of the costs to the provider of updating services, and more broadly inform ?real-world? resource allocation decisions by providing policymakers and payers with evidence on the net economic and health impact of new approaches and their fiscal viability over time. This requires considering both costs and consequences of a new intervention, often using a cost-effectiveness or cost-benefit analysis framework. The overall aim of CHERISH (Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV) is to develop and disseminate economic evidence that informs substance use disorder policy and HCV and HIV care of people who use substances. In this renewal period we will expand our focus to outcome and implementation research that is conducted at the individual, system, and community levels with the following specific aims: 1) to guide researchers in the design, implementation, and interpretation of economic analyses of treatment for substance use disorder, and HCV and HIV among people who use substances, and 2) to develop and apply methods that support economic evaluations for substance use disorder, and HCV and HIV among people who use substances with a focus on intervention implementation and adaptive interventions. Through the CHERISH Consultation Service and Research Affiliates Program, we will contribute to the development of new grant proposals with explicit economic aims, and will continue to connect with and advise qualifying researchers nationally to ensure that planned economic analyses are methodologically sound and feasible. We will expand the CHERISH Research Affiliates program so it can serve as a nationally-representative virtual community for researchers engaged in substance use disorder treatment health economic research. Working with existing studies and integrating data from third-party datasets and administrative records, we will develop analytic frameworks and tools for evaluating individual and systems-level substance use disorder and related implementation interventions. We will also develop economic evaluation methods for adaptive interventions. In collaboration with the Population Data & Modeling Core, we will assist researchers in using external data to enhance interpretation of economic evaluation results.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
2P30DA040500-06A1
Application #
10079947
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2025-04-30
Budget Start
2020-07-01
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
060217502
City
New York
State
NY
Country
United States
Zip Code
10065
Leech, Ashley A; Burgess, James F; Sullivan, Meg et al. (2018) Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States. AIDS 32:2787-2798
Behrends, Czarina N; Nugent, Ann V; Des Jarlais, Don C et al. (2018) Availability of HIV and HCV On-Site Testing and Treatment at Syringe Service Programs in the United States. J Acquir Immune Defic Syndr 79:e76-e78
Oluwoye, Oladunni; Skalisky, Jordan; Burduli, Ekaterina et al. (2018) Using a randomized controlled trial to test whether modifications to contingency management improve outcomes for heavy drinkers with serious mental illness. Contemp Clin Trials 69:92-98
Akiyama, Matthew J; Agyemang, Linda; Arnsten, Julia H et al. (2018) Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infect Dis 18:74
Assoumou, Sabrina A; Tasillo, Abriana; Leff, Jared A et al. (2018) Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis 66:376-384
Murphy, Sean M; McCollister, Kathryn E; Leff, Jared A et al. (2018) Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. Ann Intern Med :
Miclette, Matthew A; Leff, Jared A; Cuan, Isabella et al. (2018) Closing the gaps in opioid use disorder research, policy and practice: conference proceedings. Addict Sci Clin Pract 13:22
Zhang, Yongkang; Johnson, Phyllis; Jeng, Philip J et al. (2018) First Opioid Prescription and Subsequent High-Risk Opioid Use: a National Study of Privately Insured and Medicare Advantage Adults. J Gen Intern Med :
Behrends, Czarina N; Eggman, Ashley A; Gutkind, Sarah et al. (2018) A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination. J Public Health Manag Pract :
Linas, Benjamin P; Nolen, Shayla (2018) A Guide to the Economics of Hepatitis C Virus Cure in 2017. Infect Dis Clin North Am 32:447-459

Showing the most recent 10 out of 93 publications